Yes, in the sense that matters at the pharmacy counter: Wegovy and Ozempic both contain semaglutide, both are made by Novo Nordisk, and both injections are taken once a week [3] [4]. They differ in who the label is written for and how high the dose goes. Ozempic is approved for type 2 diabetes and tops out at 2 mg a week. Wegovy is approved for weight reduction, with a usual 2.4 mg dose and a 7.2 mg maximum [3] [4]. Novo Nordisk lists an Ozempic pen at $1,027.51 and a Wegovy package at $1,349.02 [5] [6].
The question usually arrives after a refusal: a plan declines one name and a friend mentions the other. Which name a prescription carries is set by the diagnosis the prescriber writes, and that decides whether the drug is billed as diabetes care or as weight treatment. How coverage splits along that line is set out in what decides your bill, and the Medicare side of it in whether Medicare covers Ozempic and Wegovy.
What each label is written for
Ozempic’s label has three uses, all in adults with type 2 diabetes. The first is better blood sugar, and the second is a lower risk of heart attack, stroke and cardiovascular death where heart disease is established. The third is a lower risk of kidney decline where chronic kidney disease is present [4]. Nothing on it covers weight loss in someone without diabetes.
Wegovy’s injection label runs the other way. It covers weight reduction in adults and in children aged 12 and older with obesity, and in adults with overweight and at least one weight-related condition [3]. It also covers heart-risk reduction in adults with established cardiovascular disease and obesity or overweight, and a form of fatty liver disease with moderate to advanced scarring [3]. It also says Wegovy should not be combined with any other semaglutide product, and Ozempic is one [3].
Where the dose ladders part
Both ladders start at 0.25 mg a week for four weeks and step up every four weeks after that [3] [4]. Ozempic moves to 0.5 mg, then to 1 mg and 2 mg when more blood-sugar control is needed, with 1 mg also the dose for its kidney use [4]. Wegovy moves through 0.5, 1 and 1.7 mg to a usual maintenance dose of 2.4 mg [3]. For patients who have tolerated 2.4 mg for at least four weeks and need more weight loss, the label allows a maximum of 7.2 mg, supplied as the Wegovy HD pen [3].
That top rung is the practical difference. Ozempic pens come in 0.25 or 0.5 mg, 1 mg and 2 mg, so no Ozempic pen delivers 2.4 mg [5]. The same molecule sits in both pens, but the label caps the dose, and the cap is where the trials part company too.
What the higher dose added in trials
Two randomized trials tested a higher semaglutide dose against the 1 mg diabetes dose. STEP 2 enrolled 1,210 adults with type 2 diabetes and overweight or obesity and assigned them to 2.4 mg, 1.0 mg or placebo for 68 weeks [1]. Weight fell 9.6% on 2.4 mg against 3.4% on placebo, and 68.8% on 2.4 mg lost at least 5% against 28.5% on placebo [1].
The cost of the higher dose showed up in side effects. Gastrointestinal adverse events were reported in 63.5% on 2.4 mg, 57.5% on 1.0 mg and 34.3% on placebo, mostly mild to moderate [1]. Adverse events of any kind ran 87.6%, 81.8% and 76.9% across the same three groups [1].
SUSTAIN FORTE tested the top of Ozempic’s own ladder. It randomized 961 adults with type 2 diabetes to 2.0 mg or 1.0 mg for 40 weeks [2]. HbA1c fell 2.2 percentage points on 2.0 mg against 1.9 on 1.0 mg, and weight fell 6.9 kg against 6.0 kg [2]. Gastrointestinal events were similar, at 34% and 31% [2]. In that trial the 2 mg step bought a little more of both. It was built to lower blood sugar, though, and a diabetes trial of 40 weeks does not stand in for a weight trial of 68.
What Novo Nordisk charges for each
Novo Nordisk publishes list prices on its NovoCare site, and it defines list price as the price set by the manufacturer before any discounts or rebates [5]. For Ozempic the page reads “Ozempic® 2 mg (1 x 3-mL pen) = $1,027.51”, and the lower doses carry the same figure [5]. For Wegovy it reads “Wegovy® pen has a list price of $1,349.02/package” [6]. The packages differ: Novo counts an Ozempic month as one pen and a Wegovy month as a box of four pens [7] [8].
The self-pay prices through NovoCare Pharmacy sit much closer together. For Ozempic the terms read “$349 per month for Ozempic® 0.25 mg, 0.5 mg, or 1 mg, and $499/month for Ozempic® 2 mg” [7]. For Wegovy they read “$349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for Wegovy® HD (semaglutide) injection 7.2 mg” [8]. Both brands start new patients at $199 a month for the first two fills at 0.25 mg and 0.5 mg, through December 31, 2026 [7] [8].
So the gap a cash buyer meets is narrower than the list prices suggest, and it sits at the top of each ladder. The reasons the list figure is so far above the cost of making the drug are covered in why semaglutide is so expensive. Why neither brand has a generic copy in the US yet is covered in whether there is a generic Ozempic.
Where a request usually stalls
On an insurance claim, the label is the first thing checked. A plan that covers diabetes drugs may approve Ozempic for a patient with type 2 diabetes and refuse Wegovy for the same patient, or require prior authorization for either. The patient often learns which only after the pharmacy runs the claim. How long that review takes, and what happens after a denial, is in how long prior authorization takes.
When the answer is no, the cash routes are the manufacturer’s own pharmacy at the prices above, or a compounded semaglutide, which is not FDA-approved and is neither Ozempic nor Wegovy. The same split between a diabetes label and a weight label runs through tirzepatide, where it separates Mounjaro from Zepbound, as laid out in whether Zepbound is the same as Mounjaro. What happened to Wegovy prescriptions once Medicare could cover the heart indication is in the fills after the cardiovascular label.